Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBT: 2023-2025

Historic EBT for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' EBT fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
  • Compass Therapeutics' EBT amounted to -$15.8 million in Q3 2025, which was up 24.92% from -$21.1 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' EBT ranged from a high of -$7.8 million in Q1 2023 and a low of -$21.1 million during Q2 2025.
  • Its 3-year average for EBT is -$13.5 million, with a median of -$13.1 million in 2024.
  • Data for Compass Therapeutics' EBT shows a maximum YoY plummeted of 61.10% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Compass Therapeutics' EBT stood at -$13.4 million in 2023, then declined by 23.55% to -$16.6 million in 2024, then declined by 29.23% to -$15.8 million in 2025.
  • Its EBT stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.